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TREATMENT OF KNEE OA WITH ACETAMINOPHEN
(3-4gr/day) DURING 12 MONTHS: A NATURALISTIC
PROSPECTIVE STUDY
C. Fernández-López1, N. Oreiro1, M. Freire1,
M. Bonome-González2, S. Reboiro1, J. Fernández-Sueiro1,
F. Galdo1, F.J. Blanco1
1Rheumatology Division. Clinical Research Unit, CH
Universitario Juan Canalejo, Coruña, Spain; 2Centro Salud de
Matogrande, Coruña, Spain
Purpose: Osteoarthritis (OA) is the more common rheumatic
diseases. Acetominophen (3-4 gr/day), is a therapeutic alterna-
tive to treat symptomatic knee OA. Effectiveness and security
data from long term studies using acetominophen in naturalistic
conditions is scarce.
To study the security and effectiveness data of acetominophen
at doses of 4gr/day in real conditions during 6 and 12 months.
Methods: This observational, naturalistic, open and prospective
clinical trial was conducted in a Spanish rheumatology clinic. All
included patients were treated with acetaminophen at doses of
4gr/day during the ﬁrst 6 months, and then doses were regulated
according symptoms of patients. Visits were performed at 3, 6,
9 and 12 months. Pain EVA and WOMAC were employed to
quantify effectiveness. Data from security were also recorded.
Results: 219 patients were included: 87.4% females, age
65.5±8.76 years and BMI 32.9±5.3. Duration of knee OA was
49.9±63.4 years. Baseline WOMAC values were: Pain = 6.9±2.8,
Stiffness = 3±1.7, Function = 25±11.7. Baseline pain-EVA was
46.1±21.4. Knee OA was bilateral in 93.0% of patients. 178
patients complete the protocol at 6 months and 139 patients
at 12 months. Pain-EVA [media (95% IC)] at 6 months was
37.1 (33.9-41.6) and 38.1 (33.9-42.2) at 12 months (p=0.01 and
p<0.001 respectively). WOMAC values at 6 months were [me-
dia (95% IC)]: Pain = 6.6 (6.1-7.2), Stiffness = 2.7 (2.5-3.0),
Function = 24.0 (22.2-25.8). WOMAC values at 12 months were:
Pain = 6.4 (5.8-6.9), Stiffness = 2.8 (2.5-3.1), Function = 24.9
(23.0-26.9). At 6 and 12 months 42.9% and 40.3% of patients
were responders according OARSI criteria. Two hundred forty
adverse events were reported, 76% of them were low level ad-
verse events. The most frequent adverse event was infections of
respiratory tract. Eight adverse events were classiﬁed as severe,
2 of them were hepatotoxic adverse events and acetaminophen
was dropped.
Conclusions: In naturalistic conditions, acetaminophen at doses
of 3-4gr/day reduces pain in patients with knee OA and it is a
secure drug.
This clinical trail was supported by Bristol-Mayers-Squibb.
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INHIBITION BY HYALURONAN OF COLLAGENASE
PRODUCTION THROUGH NUCLEAR FACTOR-κB
DOWN-REGULATION IN OSTEOARTHRITIS
CHONDROCYTES STIMULATED WITH COOH-TERMINAL
HEPARIN-BINDING FIBRONECTIN FRAGMENT
T. Yasuda
Department of Sports Medicine, Tenri University, Tenri, Japan
Purpose: Increased ﬁbronectin fragments are thought to be
involved in cartilage destruction in osteoarthritis (OA) through
their catabolic activities. At present, whether ﬁbronectin frag-
ments can activate nuclear factor (NF)-κB in OA chondrocytes
remains unknown. In addition, hyaluronan (HA) effect on ﬁ-
bronectin fragment-activated intracellular pathways remains to
be clariﬁed. This study was aimed to examine the inhibitory ef-
fect of HA on collagenase production through NF-κB activation by
COOH-terminal heparin-binding ﬁbronectin fragment (HBFN-f) in
OA chondrocytes.
Methods: OA cartilage was harvested from knee joint at re-
placement surgery, and chondrocytes were kept in monolayer
or cartilage explant cultures in the presence of HBFN-f. Se-
creted levels of matrix metalloproteinase (MMP)-1 and MMP-13
in conditioned media were determined by immunoblot analysis.
NF-κB activation and nuclear translocation were evaluated by
immunoblot analysis. Cultures were pretreated with 2700 kDa
HA to evaluate the inhibitory effect on HBFN-f action.
Results: HBFN-f enhanced MMP-1 and MMP-13 in OA carti-
lage explant culture. The speciﬁc NF-κB inhibitor, BAY11-7085
conﬁrmed the requirement of NF-κB for collagenase induction
by HBFN-f. HBFN-f activated NF-κB, leading to NF-κB nuclear
translocation in OA chondrocyte monolayer culture. Pretreatment
with HA resulted in signiﬁcant suppression of NF-κB phospho-
rylation and nuclear translocation by HBFN-f. HA also inhibited
HBFN-f-stimulated production of MMP-1 and MMP-13 in OA
cartilage explant culture.
Conclusions: The present study clearly demonstrated that
HBFN-f activated NF-κB in OA chondrocytes, while high molec-
ular weight HA inhibited such activation. When HA is therapeuti-
cally introduced into OA joints, therefore, HA could suppress the
catabolic actions of ﬁbronectin fragments like HBFN-f as a potent
NF-κB inhibitor.
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APPLYING THE HERBAL THERAPY ROSE-HIP IN
OSTEOARTHRITIS PATIENTS: A SYSTEMATIC REVIEW
AND A META-ANALYSIS
R. Christensen Sr.1, H. Lund1, E. Bartels2, A. Astrup3,
H. Bliddal1
1The Parker Institute, Frederiksberg, Denmark; 2Copenhagen
University Library, Copenhagen, Denmark; 3Department of
Human Nutrition, Copenhagen, Denmark
Purpose: To give a systematic review, with a quality assessment
and meta-analysis of clinical trials, of rose-hip supplement (a
herbal remedy) for knee and/or hip OA symptoms.
Methods: The bibliographical databases PubMed, EMBASE,
CINAHL, Scopus, Sciﬁnder, Web of Science, and PEDro, as well
as The Cochrane Controlled Trials Register and Scirus, were
searched for randomised controlled trials (RCTs) of subjects with
(knee or hip) osteoarthritis (OA) - using the terms: osteoarthritis,
osteoarthrosis, degenerative arthritis - combined with rose-hip,
rosa canina, ros* AND herb*, “hyben vital”, “Litozin”. We also did
a manual search of reference lists in review articles, manuscripts,
and supplements from rheumatology and OA journals. Inclusion,
quality scoring, and data abstraction were performed systemati-
cally by 2 independent reviewers. Outcome data were extracted
for pain and disability. For each included trial, the number of re-
sponders was estimated, and standardised mean difference was
calculated as the Effect Size (ES) for pain, and disability based
on the corresponding relevant z-statistics. We calculated Odds
Ratio’s (OR) for the number of patients responding to treatment,
supported by the Number Needed to Treat (NNT) for clinical
response. For the meta-analyses we used a (SAS) mixed lin-
ear model, but applied a restricted maximum likelihood (REML)
method.
Results: A total of four RCTs, including two with a cross-over de-
sign, were eligible for meta-analysis. This included 360 patients
with symptomatic knee and/or hip OA; 229 of these patients were
allocated to rose-hip supplement treatment. The studies had an
arithmetic mean quality score of 3.90 (78.1% max). All three
outcomes - pain, disability, and number of responders - seemed
homogenous (P>0.17), supported by the I-square: 39.5%, <0%,
and 37.5%, respectively (indicating consistency). Based on the
